Literature DB >> 30971467

Development of Molecular Methods for Rapid Differentiation of Mycoplasma gallisepticum Vaccine Strains from Field Isolates.

Kinga M Sulyok1, Zsuzsa Kreizinger1, Katinka Bekő1, Barbara Forró1, Szilvia Marton1, Krisztián Bányai1, Salvatore Catania2, Christine Ellis3, Janet Bradbury3, Olusola M Olaogun4, Áron B Kovács1, Tibor Cserép5, Miklós Gyuranecz6,7.   

Abstract

Mycoplasma gallisepticum is among the most economically significant mycoplasmas causing production losses in poultry. Seven melt-curve and agarose gel-based mismatch amplification mutation assays (MAMAs) and one PCR are provided in the present study to distinguish the M. gallisepticum vaccine strains and field isolates based on mutations in the crmA, gapA, lpd, plpA, potC, glpK, and hlp2 genes. A total of 239 samples (M. gallisepticum vaccine and type strains, pure cultures, and clinical samples) originating from 16 countries and from at least eight avian species were submitted to the presented assays for validation or in blind tests. A comparison of the data from 126 samples (including sequences available at GenBank) examined by the developed assays and a recently developed multilocus sequence typing assay showed congruent typing results. The sensitivity of the melt-MAMA assays varied between 101 and 104 M. gallisepticum template copies/reaction, while that of the agarose-MAMAs ranged from 103 to 105 template copies/reaction, and no cross-reactions occurred with other Mycoplasma species colonizing birds. The presented assays are also suitable for discriminating multiple strains in a single sample. The developed assays enable the differentiation of live vaccine strains by targeting two or three markers/vaccine strain; however, considering the high variability of the species, the combined use of all assays is recommended. The suggested combination provides a reliable tool for routine diagnostics due to the sensitivity and specificity of the assays, and they can be performed directly on clinical samples and in laboratories with basic PCR equipment.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  DIVA; Mycoplasma gallisepticumzzm321990; molecular methods; poultry; vaccine; wild-type strain

Mesh:

Substances:

Year:  2019        PMID: 30971467      PMCID: PMC6535619          DOI: 10.1128/JCM.01084-18

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  38 in total

Review 1.  Avian mycoplasmosis (Mycoplasma gallisepticum).

Authors:  S Levisohn; S H Kleven
Journal:  Rev Sci Tech       Date:  2000-08       Impact factor: 1.181

2.  Demonstration of the genetic stability of a Mycoplasma gallisepticum strain following in vivo passage.

Authors:  R D Evans; Y S Hafez; C S Schreurs
Journal:  Avian Dis       Date:  1992 Jul-Sep       Impact factor: 1.577

3.  Evaluation of a Mycoplasma gallisepticum strain exhibiting reduced virulence for prevention and control of poultry mycoplasmosis.

Authors:  R D Evans; Y S Hafez
Journal:  Avian Dis       Date:  1992 Apr-Jun       Impact factor: 1.577

4.  Characterization of pleuropneumonia-like organisms of avian origin. I. Antigenic analysis of seven strains and their comparative pathogenicity for birds.

Authors:  R YAMAMOTO; H E ADLER
Journal:  J Infect Dis       Date:  1958 Mar-Apr       Impact factor: 5.226

5.  The effect of certain antibiotics and chemical agents on pleuropneumonia-like organisms of avian origin.

Authors:  R YAMAMOTO; H E ADLER
Journal:  Am J Vet Res       Date:  1956-07       Impact factor: 1.156

6.  Differentiation of Mycoplasma gallisepticum strains using amplified fragment length polymorphism and other DNA-based typing methods.

Authors:  Yang Hong; Maricarmen García; Sharon Levisohn; Paul Savelkoul; Victoria Leiting; Inna Lysnyansky; David H Ley; Stanley H Kleven
Journal:  Avian Dis       Date:  2005-03       Impact factor: 1.577

7.  Identification of a virulence-associated determinant, dihydrolipoamide dehydrogenase (lpd), in Mycoplasma gallisepticum through in vivo screening of transposon mutants.

Authors:  P Hudson; T S Gorton; L Papazisi; K Cecchini; S Frasca; S J Geary
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

8.  Strain differentiating real-time PCR for Mycoplasma gallisepticum live vaccine evaluation studies.

Authors:  Ziv Raviv; Scott A Callison; N Ferguson-Noel; Stanley H Kleven
Journal:  Vet Microbiol       Date:  2007-11-22       Impact factor: 3.293

9.  Use of molecular diversity of Mycoplasma gallisepticum by gene-targeted sequencing (GTS) and random amplified polymorphic DNA (RAPD) analysis for epidemiological studies.

Authors:  Naola M Ferguson; Diego Hepp; Shulei Sun; Nilo Ikuta; Sharon Levisohn; Stanley H Kleven; Maricarmen García
Journal:  Microbiology       Date:  2005-06       Impact factor: 2.777

10.  Identification of fibronectin-binding proteins in Mycoplasma gallisepticum strain R.

Authors:  Meghan May; Leka Papazisi; Timothy S Gorton; Steven J Geary
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

View more
  2 in total

Review 1.  Mycoplasmas as Host Pantropic and Specific Pathogens: Clinical Implications, Gene Transfer, Virulence Factors, and Future Perspectives.

Authors:  Ali Dawood; Samah Attia Algharib; Gang Zhao; Tingting Zhu; Mingpu Qi; Kong Delai; Zhiyu Hao; Marawan A Marawan; Ihsanullah Shirani; Aizhen Guo
Journal:  Front Cell Infect Microbiol       Date:  2022-05-13       Impact factor: 6.073

Review 2.  Current status of vaccine research, development, and challenges of vaccines for Mycoplasma gallisepticum.

Authors:  Muhammad Ishfaq; Wanying Hu; Mohammad Zeb Khan; Ijaz Ahmad; Wenxin Guo; Jichang Li
Journal:  Poult Sci       Date:  2020-06-27       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.